Cargando…

APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease

BACKGROUND: Aggregation of amyloid β into plaques in the brain is one of the earliest pathological events in Alzheimer’s disease (AD). The exact pathophysiology leading to dementia is still uncertain, but the apolipoprotein E (APOE) ε4 genotype plays a major role. We aimed to identify the molecular...

Descripción completa

Detalles Bibliográficos
Autores principales:	Konijnenberg, Elles, Tijms, Betty M., Gobom, Johan, Dobricic, Valerija, Bos, Isabelle, Vos, Stephanie, Tsolaki, Magda, Verhey, Frans, Popp, Julius, Martinez-Lage, Pablo, Vandenberghe, Rik, Lleó, Alberto, Frölich, Lutz, Lovestone, Simon, Streffer, Johannes, Bertram, Lars, Blennow, Kaj, Teunissen, Charlotte E., Veerhuis, Robert, Smit, August B., Scheltens, Philip, Zetterberg, Henrik, Visser, Pieter Jelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254647/ https://www.ncbi.nlm.nih.gov/pubmed/32460813 http://dx.doi.org/10.1186/s13195-020-00628-z

Ejemplares similares

CSF Proteomic Alzheimer’s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals
por: Tijms, Betty Marije, et al.
Publicado: (2021)

Effects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition
por: Wesenhagen, Kirsten E.J., et al.
Publicado: (2022)

Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics
por: Tijms, Betty M, et al.
Publicado: (2020)

Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
por: Visser, Pieter Jelle, et al.
Publicado: (2022)

Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease
por: Visser, Pieter Jelle, et al.
Publicado: (2022)

A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort
por: Stamate, Daniel, et al.
Publicado: (2019)

Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimer’s disease biomarkers
por: Weiner, Sophia, et al.
Publicado: (2022)

Inflammatory biomarkers in Alzheimer's disease plasma
por: Morgan, Angharad R., et al.
Publicado: (2019)

Sex-Specific Metabolic Pathways Were Associated with Alzheimer’s Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort
por: Xu, Jin, et al.
Publicado: (2021)

Genome-Wide Association Study of Alzheimer’s Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery Dataset
por: Homann, Jan, et al.
Publicado: (2022)

Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer’s Disease biomarker discovery cohort
por: Kim, Min, et al.
Publicado: (2019)

The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics
por: Bos, Isabelle, et al.
Publicado: (2018)

Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset
por: Hong, Shengjun, et al.
Publicado: (2020)

Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
por: Shi, Liu, et al.
Publicado: (2019)

MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study
por: ten Kate, Mara, et al.
Publicado: (2018)

Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer’s Disease Multimodal Biomarker Discovery Cohort
por: Westwood, Sarah, et al.
Publicado: (2020)

Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation
por: Neumann, Alexander, et al.
Publicado: (2022)

Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning
por: Neumann, Alexander, et al.
Publicado: (2023)

A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer’s disease
por: Skillbäck, Tobias, et al.
Publicado: (2017)

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
por: Cicognola, Claudia, et al.
Publicado: (2021)

Peptidome Analysis of Cerebrospinal Fluid by LC-MALDI MS
por: Hölttä, Mikko, et al.
Publicado: (2012)

Harmonization and standardization of biofluid‐based biomarker measurements for AT(N) classification in Alzheimer's disease
por: Giangrande, Chiara, et al.
Publicado: (2023)

Unbiased estimates of cerebrospinal fluid β-amyloid 1–42 cutoffs in a large memory clinic population
por: Bertens, Daniela, et al.
Publicado: (2017)

Abnormal cerebrospinal fluid levels of amyloid and tau are associated with cognitive decline over time in cognitively normal older adults: A monozygotic twin study
por: Tomassen, Jori, et al.
Publicado: (2022)

Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer’s Disease Pathology
por: Shi, Liu, et al.
Publicado: (2020)

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease
por: Duits, Flora H., et al.
Publicado: (2018)

Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers
por: Camporesi, Elena, et al.
Publicado: (2021)

Levels of ADAM10 are reduced in Alzheimer’s disease CSF
por: Sogorb-Esteve, Aitana, et al.
Publicado: (2018)

Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal
por: Vermunt, Lisa, et al.
Publicado: (2019)

CSF proteomic signature predicts progression to Alzheimer's disease dementia
por: Vromen, Eleonora M., et al.
Publicado: (2022)

Onset of Preclinical Alzheimer Disease in Monozygotic Twins
por: Konijnenberg, Elles, et al.
Publicado: (2021)

Corrigendum to “Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer’s disease” [Clin. Mass Spectrom. 14 (Part B) (2019) 74–82]
por: Hansson, Karl, et al.
Publicado: (2022)

Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment
por: ten Kate, Mara, et al.
Publicado: (2017)

Plasma Proteomic Biomarkers Relating to Alzheimer’s Disease: A Meta-Analysis Based on Our Own Studies
por: Shi, Liu, et al.
Publicado: (2021)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
por: Blennow, Kaj, et al.
Publicado: (2015)

The Past and the Future of Alzheimer’s Disease Fluid Biomarkers(1)
por: Blennow, Kaj, et al.
Publicado: (2018)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
por: Zetterberg, Henrik, et al.
Publicado: (2021)

Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals
por: Ingala, Silvia, et al.
Publicado: (2021)

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
por: Nilsson, Johanna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ss93dea69l5m5s32v77mhc9e6f